Antipsychotic prescribing do conflict of interest policies make a difference?

Medical Care

Volumn 53, Issue 4, 2015, Pages 338-345

  Anderson, Timothy S ^a   Huskamp, Haiden A ^b   Epstein, Andrew J ^c   Barry, Colleen L ^d   Men, Aiju ^e   Berndt, Ernst R ^f   Horvitz Lennon, Marcela ^g   Normand, Sharon Lise ^b,h   Donohue, Julie M ^e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g RAND CORPORATION   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

academic medical center; antipsychotics; pharmaceutical policy; practice variation

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; FLUOXETINE; ILOPERIDONE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CONFLICT OF INTEREST; CONTROLLED STUDY; FEMALE; HEALTH CARE POLICY; HUMAN; HUMAN EXPERIMENT; MALE; MEDICAL EDUCATION; MEDICATION COMPLIANCE; NORMAL HUMAN; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; UNIVERSITY HOSPITAL; CLINICAL PRACTICE; DRUG UTILIZATION; PSYCHIATRY; STATISTICS AND NUMERICAL DATA;

ACADEMIC MEDICAL CENTERS; ANTIPSYCHOTIC AGENTS; CONFLICT OF INTEREST; DRUG UTILIZATION; FEMALE; HUMANS; MALE; PRACTICE PATTERNS, PHYSICIANS'; PSYCHIATRY;

EID: 84925938677     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000329     Document Type: Article

References (40)

1. Austad KE, Avorn J, Kesselheim AS. Medical students' exposure to and attitudes about the pharmaceutical industry: a systematic review. PLoS Med. 2011; 8: e1001037
2. Kornfield R, Donohue JM, Berndt ER, et al. Promotion of prescription drugs to consumers and providers, 2001-2010. PLoS One. 2013; 8: e55504
3. Spurling GK, Mansfield PR, Montgomery BD, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med. 2010; 7: e1000352
4. Lo B, Field MJ. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: Institute of Medicine; 2009
5. Association of American Medical Colleges. Protecting Patients, Preserving Integrity, Advancing Health: Accelerating the Implementation of COI Policies in Human Subjects Research. Washington, DC: Association of American Medical Colleges; 2008
6. Association of American Medical Colleges. Industry Funding of Medical Education: Report of an AAMC Task Force. Washington, DC: Association of American Medical Colleges; 2008
7. American Medical Association. Conflict of Interest Guidelines for Organized Medical Staffs. Chicago, IL: American Medical Association; 2007
8. Freshwater DM, Freshwater MF. Failure by deans of academic medical centers to disclose outside income. Arch Intern Med. 2011; 171: 586-587
9. Trudo H, Meyer T. Dollars for docs: the top earners 2012. 2012. Available at: http://www.propublica.org/article/dollars-for-docs-The-Topearners. Accessed September 5, 2013
10. Berndt ER, Bui LT, Reiley DH, et al. Information, marketing, and pricing in the US anti-ulcer drug market. Am Econ Rev. 1995; 85: 100-105
11. Donohue JM, Berndt ER. Direct-To-consumer advertising and choice of antidepressant. J Public Policy Market. 2004; 23: 115-127
12. Chimonas S, Evarts SD, Littlehale SK, et al. Managing conflicts of interest in clinical care: the "race to the middle" at US medical schools. Acad Med. 2013; 88: 1464-1470
13. Austad KE, Avorn J, Franklin JM, et al. Changing interactions between physician trainees and the pharmaceutical industry: a national survey. J Gen Intern Med. 2013; 28: 1064-1071
14. King M, Essick C, Bearman P, et al. Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis. BMJ. 2013; 346: f264
15. Epstein AJ, Busch SH, Busch AB, et al. Does exposure to conflict of interest policies in psychiatry residency affect antidepressant prescribing? Med Care. 2013; 51: 199-203
16. IMS Institute for Health InformaticsThe use of medicines in the United States: review of 2010. 2011. Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS Institute/Static File/IHII-UseOfMed-report.pdf. Accessed March 3, 2014
17. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209-1223
18. Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second-vs. first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry. 2006; 63: 1079-1087
19. Tandon R, Carpenter WT, Davis JM. First-And second-generation antipsychotics: learning from CUtLASS and CATIE. Arch Gen Psychiatry. 2007; 64: 977-978
20. Huskamp HA, O'Malley AJ, Horvitz-Lennon M, et al. How quickly do physicians adopt new drugs? The case of second-generation antipsychotics. Psychiatr Serv. 2013; 64: 324-330
21. Leonhauser M. Antipsychotics: multiple indications drive growth. Market Watch. 2012. Available at: http://www.imshealth.com/ims/Global/Content/Corporate/Press Room/IMS in the News/Documents/PM360-IMS-Antipsychotics-0112.pdf. Accessed November 12, 2013
22. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011; 20: 177-184
23. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the Department of Veterans Affairs Health Care System. Psychiatr Serv. 2009; 60: 1175-1181
24. Nyweide DJ, Weeks WB, Gottlieb DJ, et al. Relationship of primary care physicians' patient caseload with measurement of quality and cost performance. JAMA. 2009; 302: 2444-2450
25. Association of American Medical Colleges. Organizational characteristics database. Available at: https://http://www.aamc.org/data/ocd/. Accessed August 9, 2013
26. American Medical Student Association. AMSA PharmFree Scorecard 2013. 2013. Available at: http://www.amsascorecard.org. Accessed July 20, 2013
27. Institute on Medicine as a Profession. IMAP conflict of interest database. 2014. Available at: http://www.imapny.org/conflicts-of-interest/conflictsof-interest-2/. Accessed March 3, 2014
28. Schneeweiss S, Glynn RJ, Avorn J, et al. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-Time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005; 58: 98-102
29. Hamann J, Adjan S, Leucht S, et al. Psychiatric decision making in the adoption of a new antipsychotic in Germany. Psychiatr Serv. 2006; 57: 700-703
30. Hoblyn J, Noda A, Yesavage JA, et al. Factors in choosing atypical antipsychotics: Toward understanding the bases of physicians' prescribing decisions. J Psychiatr Res. 2006; 40: 160-166
31. Gelman A, Hill J. Data Analysis Using Regression and Multilevel/Hierarchical Models Chapter 14. New York, NY: Cambridge University Press; 2007; 321
32. Hoffmann TC, Montori VM, Mar CD. The connection between evidence-based medicine and shared decision making. JAMA. 2014; 312: 1295-1296
33. Donohue JM, O'Malley AJ, Horvitz-Lennon M, et al. Changes in physician antipsychotic prescribing preferences, 2002-2007. Psychiatr Serv. 2014; 65: 315-322
34. Donohue JM, Berndt ER, Rosenthal M, et al. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med Care. 2004; 42: 1176-1185
35. Dusetzina SB, Busch AB, Conti RM, et al. Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. Pharmacoepidemiol Drug Saf. 2012; 21: 1251-1260
36. Korn D, Carlat D. Conflicts of Interest in medical education recommendations from the Pew Task Force on medical conflicts of interest. JAMA. 2013; 310: 2397-2398
37. Ornstein C. Our first dive into the new open payments system. 2014. Available at: http://www.propublica.org/article/our-first-dive-into-Thenew-open-payments-system. Accessed October 5, 2014
38. Stossel T. Has the hunt for conflicts of interest gone to far? Yes. BMJ. 2008; 336: 476
39. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2010; 290: 252-255
40. Rosenthal MB, Berndt ER, Donohue JM, et al. Promotion of prescription drugs to consumers. N Engl J Med. 2002; 346: 498-505